TRAVERT 10% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVERT 10% IN PLASTIC CONTAINER (TRAVERT 10% IN PLASTIC CONTAINER).
Travert 10% (invert sugar) provides a source of carbohydrate calories and water for hydration. Invert sugar is hydrolyzed to glucose and fructose, which are metabolized via glycolysis and the Krebs cycle to produce ATP. It also promotes glycogen deposition and spares protein catabolism.
| Metabolism | Invert sugar is rapidly hydrolyzed to glucose and fructose by invertase in the intestine or administered directly IV. Glucose and fructose are metabolized via glycolysis and the Krebs cycle in the liver and peripheral tissues. Fructose is primarily metabolized in the liver via fructokinase to fructose-1-phosphate, then to trioses entering glycolysis or gluconeogenesis. |
| Excretion | Primarily renal as unchanged drug (approx. 90%) and as metabolites (approx. 10%). Fecal excretion is negligible (<1%). |
| Half-life | 0.3-0.7 hours (20-40 minutes) in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 0% (not bound to plasma proteins due to high polarity). |
| Volume of Distribution | 0.25-0.3 L/kg; distributes primarily in extracellular fluid volume. |
| Bioavailability | Not applicable; administered only by intravenous route (100% bioavailability by definition). |
| Onset of Action | Intravenous: immediate onset within minutes. |
| Duration of Action | 1-2 hours following a single dose; sustained infusion maintains effect while infusing. |
| Molecular Weight | 180.16 |
Intravenous infusion: 500-1000 mL of 10% solution administered over 1-3 hours, repeated as needed based on fluid and electrolyte requirements.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria; in oliguric patients, use with caution and monitor fluid balance; no dose adjustment specified for GFR-based modifications. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to risk of fluid overload. |
| Pediatric use | Intravenous infusion: 2-5 mL/kg of 10% solution, administered over 1-3 hours, repeated as clinically indicated. |
| Geriatric use | Due to decreased renal function and higher risk of fluid overload, use lower initial doses and monitor electrolytes and fluid status closely. |
| 1st trimester | Travert 10% (invert sugar) is generally considered safe; used as a caloric source in parenteral nutrition. No known teratogenicity in animal studies. |
| 2nd trimester | Safe for use when clinically indicated; monitor maternal glucose levels. |
| 3rd trimester | Safe for use; avoid overhydration and electrolyte disturbances in the peripartum period. |
Clinical note
Comprehensive clinical and safety monograph for TRAVERT 10% IN PLASTIC CONTAINER (TRAVERT 10% IN PLASTIC CONTAINER).
| Placental transfer | Invert sugar (fructose and glucose) crosses the placenta by facilitated diffusion; fetal levels approximate maternal levels. |
| Breastfeeding | Invert sugar is a normal constituent of human milk; exogenous infusion is unlikely to affect the infant. Use with caution if maternal glucose intolerance exists. |
■ FDA Black Box Warning
Solutions containing invert sugar should not be administered simultaneously with blood through the same infusion set because of the possibility of agglutination or hemolysis.
| Serious Effects |
Severe fructose intoleranceHereditary fructose intoleranceHyperglycemia hyperosmolar stateSevere dehydration with hypernatremia
| Precautions | Use with caution in patients with hepatic or renal impairment, metabolic disorders (e.g., diabetes mellitus), or fluid/electrolyte imbalances. Monitor blood glucose and electrolytes. Rapid infusion may cause hyperglycemia, osmotic diuresis, or hyperosmolar syndrome. Do not administer if solution is discolored or contains particulates. |
| Food/Dietary | No direct food interactions. However, oral intake should be monitored as this solution provides calories. Avoid excessive oral sugar intake to prevent hyperglycemia. |
Loading safety data…
| Lactation Rating |
| Safe |
| Teratogenic Risk | Intravenous dextrose solutions are essential for maternal and fetal hydration and caloric support. No teratogenic effects have been reported with standard clinical use. However, rapid correction of maternal hypoglycemia or hyperglycemia may cause fetal hyperinsulinism or rebound hypoglycemia. Use with caution in conditions associated with fluid overload (e.g., preeclampsia). Fetal monitoring is recommended during administration in compromised pregnancies. |
| Fetal Monitoring | Monitor maternal blood glucose and electrolyte levels, especially in diabetic or glucose-intolerant patients. Assess fluid balance and signs of fluid overload (edema, pulmonary crackles). Fetal heart rate monitoring is recommended during use in pregnancy complicated by gestational diabetes or fetal compromise. Observe for maternal hyperglycemia or hypoglycemia after infusion. |
| Fertility Effects | No adverse effects on fertility have been reported with intravenous dextrose solutions at therapeutic doses. No data suggest impairment of reproductive function. Dextrose is a physiological energy source and does not interfere with reproductive hormones or gametogenesis. |
| Clinical Pearls | TRAVERT 10% is a hypertonic solution (10% invert sugar in water) used for parenteral nutrition. Infuse via central line due to high osmolarity (~555 mOsm/L). Monitor serum glucose and electrolytes, especially potassium and phosphate, to avoid refeeding syndrome. Use with caution in patients with renal impairment, as fluid overload may occur. Do not administer if cloudy or contains crystals. |
| Patient Advice | This solution is given through a vein to provide calories and fluids when you cannot eat or drink enough. · You may experience changes in blood sugar; report symptoms like excessive thirst, frequent urination, or headache. · Notify your nurse if you have pain, redness, or swelling at the IV site. · Tell your doctor if you have a history of kidney problems, diabetes, or electrolyte imbalances. · Your blood sugar and electrolyte levels will be checked regularly during treatment. |